VANCOUVER, BC / ACCESSWIRE / June 15, 2020 / Stillcanna Inc. (OTC PINK:SCNNF) (STIL.CN) (FRANKFURT:A2PEWA) (“STIL” or the “Company”) is pleased to announce that it has signed a supply agreement with Brains Bioceutical Corp (“Brains”) to supply bulk CBD for processing to their European operations.
Brains is a global leader of plant-based cannabidiol (CBD) as an Active Pharmaceutical Ingredient (API) for both Pharmaceutical and Nutraceutical use. Brains is one of the few certified phyto-cannabinoid CBD API manufacturers in Europe. Brains’ CBD API (its primary offering to the market) has GMP certification (MHRA) for both human and veterinary use. Brains API is currently being used in various clinical trials around the globe.
“Stillcanna is pleased to have the opportunity to work with a company as professional and dedicated to quality as Brains,” stated Jason Dussault, Chief Executive Officer of Stillcanna. “As one of the few companies to have a CBD API product Brains have reached the pinnacle of the industry and we look forward to meeting their high standards for a consistent, high quality product.”
Stillcanna is also pleased to announce it has begun it’s Novel Food Application and has hired Global Regulatory Services of the UK, an award winning global consulting firm with a specialty in Novel Food applications. Stillcanna has submitted its active ingredients for both stability and toxicology. As required within certain EU markets Stillcanna intends to have its Novel Food Application validated prior to the February 2021 deadline and remain market compliant in 2021 and beyond.
“Stillcanna has done a good job positioning itself as a bulk CBD manufacturer for the European market,” stated Ricky Brar, CEO and Chairman of Brains. “Even though the company is relatively new to the space we have complete confidence in their ability to meet our stringent supply guidelines and envision a close working relationship moving forward.”
About Brains Bioceutical Corp.
Brains Bioceutical Corp (“Brains”), www.brainsbio.com is a leader in GMP-certified production of naturally-sourced CBD active pharmaceutical ingredients (API) for the Pharmaceutical and Nutraceutical industries. Brains Bioceutical is one of the only CBD active pharmaceutical ingredient (API) manufacturers in production today. Along with their dedicated medical products Brains has a robust line of over the counter CBD products that are distributed throughout Europe and both North and South America.
About Stillcanna Inc.
Stillcanna Inc. (STIL.CN) www.stillcanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe. The Company feels its proprietary intellectual property allows it to extract CBD at a lower cost. The Company recently completed the acquisition of Olimax NT SP. Z .O.O, a multi-generational hemp agricultural firm that is expected to increase the Company’s market share in the European CBD industry.